Syncope, or transient loss of consciousness (TLOC), is a common clinical presentation, accounting for 1-3% of emergency department visits. Despite its prevalence, determining the underlying cause of syncope can be challenging due to its multifactorial nature. This article aims to provide a comprehensive approach to the evaluation and management of syncope.
Syncope is primarily a symptom, not a diagnosis. It is typically due to global cerebral hypoperfusion and is characterized by a rapid onset, short duration, and complete spontaneous recovery. It can be categorized into three main types: reflex (or neurally mediated), orthostatic hypotension, and cardiac syncope.
The primary goal in the evaluation of syncope is to identify those patients at risk for serious outcomes. A thorough history and physical examination, including orthostatic blood pressure measurements, can often lead to a diagnosis. Specific diagnostic tests, such as electrocardiogram (ECG), echocardiography, or tilt-table testing may be needed based on clinical suspicion.
Management strategies should be tailored to the underlying cause. Reflex syncope often requires no specific treatment other than patient education and reassurance. Orthostatic hypotension may be managed with lifestyle modifications and pharmacotherapy. Cardiac syncope, however, may indicate serious underlying heart disease and warrants further evaluation and possible intervention.
The prognosis of syncope is largely dependent on the underlying cause. While reflex and orthostatic syncope are generally benign, cardiac syncope can be associated with increased morbidity and mortality. Therefore, accurate diagnosis and appropriate management are crucial.
Understanding the complexities of syncope is essential for healthcare professionals. A comprehensive approach that includes careful history taking, physical examination, and judicious use of diagnostic tests can aid in identifying the underlying cause and guiding appropriate management. By doing so, we can improve patient outcomes and reduce healthcare utilization related to syncope.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Health researchers discuss Medicaid cancer screening trends, best practices
3.
Taking Charge of Your Cancer Journey.
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation